Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C2H4NO2.Cu.H2O |
| Molecular Weight | 229.679 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Cu++].NCC([O-])=O.NCC([O-])=O
InChI
InChIKey=IBCBKVAHJPKRLA-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.Cu.H2O/c2*3-1-2(4)5;;/h2*1,3H2,(H,4,5);;1H2/q;;+2;/p-2
| Molecular Formula | C2H5NO2 |
| Molecular Weight | 75.0666 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Cu |
| Molecular Weight | 63.546 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlDOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.ncbi.nlm.nih.gov/pubmed/16971307https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www.ncbi.nlm.nih.gov/pubmed/6526221http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfCurator's Comment: description was created based on several sources, including
https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlDOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.ncbi.nlm.nih.gov/pubmed/16971307https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www.ncbi.nlm.nih.gov/pubmed/6526221http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdf
Curator's Comment: description was created based on several sources, including
https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1
Cupric oxide is the oxide of the copper with the chemical formula of CuO. It is used in the ceramic industry for imparting blue, green or red tints in glasses, glazes and enamels. Cupric oxide is also used as a source for copper in food supplements. Copper is an essential nutrient and a normal constituent of the diet in man and animals. The average daily dietary requirement for copper in humans has been estimated at 0.03 mg/kg body weight. Although rare, copper deficiency has been induced by supplemental zinc therapy.
Originator
Sources: Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).http://pubs.acs.org/doi/abs/10.1021/ja01512a012
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1075246 |
3.42 µM [Ki] | ||
Target ID: P00450 Gene ID: 1356.0 Gene Symbol: CP Target Organism: Homo sapiens (Human) |
|||
Target ID: Glutathione S-transferase, rat, liver |
|||
Target ID: GO:0072593 |
|||
Target ID: CHEMBL354 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Preventing | Cupric glycinate Approved UseIndications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity. |
|||
| Primary | COPPER•MAX Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
|||
| Preventing | COPPER Approved UseCopper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
|||
| Preventing | COPINOX Approved UseCopinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Determination of protein by the biuret reaction using cupric hydroxide suspension reagent. | 1960 |
|
| Efficacy of burning, tillage, and biocides in controlling bacteria released at field sites and effects on indigenous bacteria and fungi. | 1992 Apr |
|
| The effect of various fluoride compounds on the development of experimental root surface caries in hamsters. | 1995 Dec |
|
| The genetics of tasting in mice. VII. Glycine revisited, and the chromosomal location of Sac and Soa. | 1995 Oct |
|
| Copper Fluoride Luminescence during UV Photofragmentation of Bis(1,1,1,5,5,5-hexafluoro-2,4-pentanedionato)copper(II) in the Gas Phase. | 1996 Aug 14 |
|
| Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. | 2000 Jul |
|
| The effectiveness of ecologically acceptable ways of protection of field-grown tomato (Lycopersicon lycopersicum (L.) Karsten) from tomato late blight (Phytophthora infestans (Mont.) de Bary) in extreme weather conditions. | 2001 |
|
| Direct catalytic aldol-type reactions using RCH2CN. | 2003 Aug 21 |
|
| Antioxidant activity of olive pulp and olive oil phenolic compounds of the arbequina cultivar. | 2005 Mar 23 |
|
| Cu(II) acetate- and Mn(III) acetate-mediated radical reactions of [60]fullerene with ketonic compounds. | 2005 Mar 7 |
|
| X-ray absorption spectroscopy study of a copper-containing material after thermal treatment. | 2006 Apr 17 |
|
| Acute copper toxicity following copper glycinate injection. | 2006 Nov |
|
| A spectroscopic and thermoanalytical study of the mineral hoganite. | 2007 May |
|
| Enhanced copper release from pipes by alternating stagnation and flow events. | 2007 Nov 1 |
|
| Bioavailability of copper from copper glycinate in steers fed high dietary sulfur and molybdenum. | 2008 Jan |
|
| Synthesis and structural investigation of mono- and polynuclear copper complexes of 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide. | 2008 Nov 1 |
|
| Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes. | 2009 Jan 16 |
|
| Insight in the transport behavior of copper glycinate complexes through the porcine gastrointestinal membrane using an Ussing chamber assisted by mass spectrometry analysis. | 2010 Apr |
|
| Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers. | 2010 Feb 3 |
|
| A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. | 2010 Nov 3 |
|
| Copper sulfide nanoparticles for photothermal ablation of tumor cells. | 2010 Oct |
|
| Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study. | 2011 Apr |
|
| Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications. | 2011 Oct 15 |
|
| Expeditious synthesis of phenanthrenes via CuBr2-catalyzed coupling of terminal alkynes and N-tosylhydrazones derived from o-formyl biphenyls. | 2011 Oct 7 |
|
| Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. | 2012 Apr |
|
| Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3. | 2012 Feb |
|
| CuBr2--a new multiferroic material with high critical temperature. | 2012 May 8 |
|
| Evaluation of topically applied copper(II) oxide nanoparticle cytotoxicity in human skin organ culture. | 2013 Feb |
|
| Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF. | 2013 Jan 18 |
|
| Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates. | 2013 May |
|
| Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses. | 2013 Nov |
|
| Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties. | 2013 Nov 25 |
|
| The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells. | 2013 Oct 24 |
|
| SILAC-based quantitative proteomic analysis of human lung cell response to copper oxide nanoparticles. | 2014 |
|
| Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts. | 2014 |
|
| Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions. | 2014 |
|
| Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics. | 2014 Feb 26 |
|
| Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells. | 2014 Jul |
|
| Electron induced surface reactions of organometallic metal(hfac)₂ precursors and deposit purification. | 2014 Jun 11 |
|
| CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin. | 2015 Jun |
|
| A Facile Strategy for Catalyst Separation and Recycling Suitable for ATRP of Hydrophilic Monomers Using a Macroligand. | 2016 Jan |
|
| Dissecting copper homeostasis in diabetes mellitus. | 2017 Apr |
|
| Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride. | 2017 Apr 1 |
|
| Roles of Copper-Binding Proteins in Breast Cancer. | 2017 Apr 20 |
|
| Supplementation with copper edetate in control of Haemonchus contortus of sheep, and its effect on cholinesterase's and superoxide dismutase activities. | 2017 Feb |
|
| Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders. | 2017 Jul |
|
| Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis. | 2017 Jul |
|
| Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy. | 2017 Jun |
|
| Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine. | 2017 Jun 15 |
|
| Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells. | 2017 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc
Curator's Comment: Veterinary drug
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration:
Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:50:39 UTC 2022
by
admin
on
Fri Dec 16 18:50:39 UTC 2022
|
| Record UNII |
163J4O4DFH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
163J4O4DFH
Created by
admin on Fri Dec 16 18:50:39 UTC 2022 , Edited by admin on Fri Dec 16 18:50:39 UTC 2022
|
PRIMARY | |||
|
71587023
Created by
admin on Fri Dec 16 18:50:39 UTC 2022 , Edited by admin on Fri Dec 16 18:50:39 UTC 2022
|
PRIMARY | |||
|
DTXSID20171302
Created by
admin on Fri Dec 16 18:50:39 UTC 2022 , Edited by admin on Fri Dec 16 18:50:39 UTC 2022
|
PRIMARY | |||
|
18253-80-0
Created by
admin on Fri Dec 16 18:50:39 UTC 2022 , Edited by admin on Fri Dec 16 18:50:39 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
